Press Releases
Below you will find the latest press releases from Evolva. You are also welcome to dive into the archive and browse our press releases from there as well:
Latest Press Releases
Reinach, Switzerland, 9 May 2012 – The Annual General Meeting of Evolva Holding SA (SIX: EVE) has approved all proposals put forward by the Board of Directors.
Reinach, Switzerland, 3 May 2012 – Evolva Holding SA (SIX: EVE) today announced that it has expanded its collaboration with International Flavors & Fragrances Inc. (NYSE: IFF), one of the world’s leading creators and manufacturers of flavours and fragrances for consumer products.
Reinach, Switzerland, 22 March 2012 – Evolva Holding SA (SIX: EVE) today announced its financial results for the period 1 January to 31 December 2011. The annual report is available on Evolva’s website.
Download:
Reinach, Switzerland, 5 March 2012 - Evolva Holding SA (SIX: EVE) today announced that Chief Scientific Officer Prof. Jutta Heim, will present data on Evolva’s promising novel antibiotic EV-035 at the conference “Superbugs & Superdrugs – A Focus on Antibacterials” in London on Monday 5 March 2012, at 1.45 PM (GMT).
Reinach, Switzerland, 29 February 2012 - Evolva Holding SA (SIX: EVE) today announced that its project with the US Army Research Office (ARO), conducted as part of the Transformational Medical Technology Initiative’s mission to prevent and address biowarfare threats, has been completed successfully.
Reinach, Switzerland, 2 January 2012 - Evolva Holding SA (SIX: EVE) today announced the signing of an agreement with Roquette Frères SA for joint research and development of novel and optimised biosynthetic production routes for an ingredient with important applications in food products. Roquette is a world leader in the area of nutrition and other products based on raw vegetable materials.
Reinach, Switzerland, 14 December 2011 – Evolva Holding SA (SIX: EVE) today announced that the Russian Patent Office has granted patent protection for EV-077 in the treatment of complications of diabetes for a term extending to 2026. This is the first patent granted covering EV-077. EV-077 patent applications are currently pending in Australia, Brazil, Canada, China, Europe, Hong Kong, India, Japan, Mexico and the USA. Evolva has filed related applications with the aim to extend the protection for its EV-077 portfolio to 2031 and beyond.
Reinach, Switzerland, 8 December 2011 – Evolva Holding SA (SIX: EVE) today announced that Roche (SIX: ROG, RO; OTCQX: RHHBY) has confirmed that Evolva has achieved the second milestone in their collaboration.
Reinach, Switzerland, 15 November 2011 – Evolva Holding SA (SIX: EVE) today announced that the European Commission has approved the use of steviol glycosides in food and beverages in the European Union 1). After the earlier clearance by regulators in the US and many other regions of the world, this marks a major breakthrough in the acceptance of Stevia as a natural, zero-calorie sweetener.
Reinach, Switzerland, 11 November 2011 – Evolva Holding SA (SIX: EVE) announced today that, for personal reasons, Alexandra Santana Sorensen will leave the company as of 29 February 2012. Dr. Sorensen’s responsibilities will be reallocated amongst the existing management team.
- 1 of 8
- ››
Press & Investors
Nutrition & Consumer
Pharmaceuticals
Stay Informed
